secwatch.observer — SEC 8-K summary
======================================

Issuer:     AETHLON MEDICAL INC (AEMD)
CIK:        0000882291
Form:       8-K
Filed at:   2026-08-13T20:15:36+00:00
Accession:  0001683168-26-006344
Event type: earnings
Sentiment:  neutral
Materiality: 0.50
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aethlon Medical reports Q1 FY2027 results; cash $4.9M, raises $4M post-quarter
------------------------------------------------------------------------------

- Cash and cash equivalents ~$4.9M as of June 30, 2026; raised ~$4.0M gross in public offering after quarter-end.
- Operating expenses decreased 11.9% to ~$1.6M vs $1.8M in prior-year quarter.
- First participant dosed in third/final cohort of Phase 1 oncology study in Australia; early biomarker signals support Hemopurifier.
- Long COVID manuscript accepted for publication in International Journal of Molecular Sciences.
- Company believes cash resources sufficient to fund operations for at least next 12 months.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/882291/000168316826006344/0001683168-26-006344-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/882291/000168316826006344/aethlon_8k.htm
  HTML page:      https://secwatch.observer/filing/0001683168-26-006344

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer